You are here

Journal of clinical oncology : official journal of the American Society of Clinical Oncology DOI:10.1200/JCO.2010.28.1675

Predicting relapse in patients with medulloblastoma by integrating evidence from clinical and genomic features.

Publication TypeJournal Article
Year of Publication2011
AuthorsTamayo, P, Cho, YJ, Tsherniak, A, Greulich, H, Ambrogio, L, Schouten-van Meeteren, N, Zhou, T, Buxton, A, Kool, M, Meyerson, M, Pomeroy, SL, Mesirov, JP
JournalJournal of clinical oncology : official journal of the American Society of Clinical Oncology
Volume29
Issue11
Pages1415-23
Date Published2011/04/10
ISSN0732-183X
Abstract

Despite significant progress in the molecular understanding of medulloblastoma, stratification of risk in patients remains a challenge. Focus has shifted from clinical parameters to molecular markers, such as expression of specific genes and selected genomic abnormalities, to improve accuracy of treatment outcome prediction. Here, we show how integration of high-level clinical and genomic features or risk factors, including disease subtype, can yield more comprehensive, accurate, and biologically interpretable prediction models for relapse versus no-relapse classification. We also introduce a novel Bayesian nomogram indicating the amount of evidence that each feature contributes on a patient-by-patient basis.

URLhttp://www.jco.org/cgi/pmidlookup?view=long&pmid=21357789
DOI10.1200/JCO.2010.28.1675
Pubmed

http://www.ncbi.nlm.nih.gov/pubmed/21357789?dopt=Abstract